SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: ezetimibe-simvastatin (Vytorin®)

MEMBER & PRESCRIBER IN	FORMATION: Authorization may be delayed if incomplete.		
Member Name:			
Member Sentara #:			
Prescriber Name:			
	Date:		
Office Contact Name:			
	Fax Number:		
DEA OR NPI #:			
DRUG INFORMATION: Author			
Drug Form/Strength:			
Dosing Schedule:	Length of Therapy:		
Diagnosis:	ICD Code, if applicable:		
Weight:	Date:		
Recommended Dosage: 1 tablet one			
CLINICAL CRITERIA. Check h	pelow all that apply. All criteria must be met for approval. To suppo		

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

☐ Member has tried and failed <u>TWO</u> of the following high intensity statins, or statin therapy at maximally tolerated dose for at least 12 consecutive weeks and did <u>NOT</u> achieve LDL cholesterol goal (verified by chart notes or pharmacy paid claims; check all that apply)

High-intensity	Moderate-intensity	Low-intensity
□ atorvastatin 40-80 mg	□ atorvastatin 10-20 mg	□ simvastatin 10 mg
□ rosuvastatin 20-40 mg	□ rosuvastatin 5-10 mg	□ pravastatin 10-20 mg
	□ simvastatin 20-40 mg	□ lovastatin 20 mg
	□ pravastatin 40-80 mg	☐ fluvastatin 20-40 mg
	☐ fluvastatin 40 mg BID	

PA ezetimibe-simvastatin (Vytorin) (CORE)

(0 . 10		,
(Continued fi	rom previous	page

Provider has submitted the results of member's lipid panel showing further reduction in LDL cholester is required despite compliant use of maximally tolerated statin monotherapy			
Current LDL-C: LDL	-C Goal:		
Member has tried and had an adequate response with a statin therapy (such as simvastatin) and ezetimibe used at the same time			
Provider has submitted chart notes to document the clinical rationale for why requested combination age is medically necessary and not only for convenience			

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *